GRIN2B and schizophrenia: While further studies are warranted to determine the functional implications of this reduction and if this reduction is common to other GluN2 subunits or hippocampal subregions, our findings provide preliminary support for the development of GluN2B selective positive modulators as a novel therapy for schizophrenia, especially the cognitive dysfunctions.